Palantir Technologies Inc. announced that it has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to support the agency's mission to accelerate better health outcomes. Palantir's AIP and Foundry software will help the agency drive key workflows by providing a data strategy and infrastructure that will underpin business operations and enable continuous improvement. The contract is worth $19 million over 2 years.

The Advanced Research Projects Agency for Health mission mandate is to accelerate better health outcomes for everyone by supporting the development of high-impact solutions to society's most challenging health problems. The agency advances high-potential, high-impact biomedical and health research that cannot be readily accomplished through traditional research or commercial activity. Investing in an enterprise data strategy provides the organization with the continuous feedback loop to accelerate innovation. Ultimately, this approach enables ARPA-H to track and learn from outcomes to accomplish their bold goals--while remaining accountable to the Government and the public.

To meet the ambitious goals laid out by the agency, ARPA-H has partnered with Palantir to provide the data infrastructure for ARPA-H's core operations in order to rapidly collect, synthesize, analyze, and make decisions from a range of data sources while ensuring security and privacy controls meet and exceed the mandatory standards. This approach will enable critical workflows based on commercial best practices, including but not limited to: program strategy, planning and oversight, financial and performance management, and the ability to track and analyze return on investment. Palantir's platform ensures that ARPA-H programs are operating within a consistent data strategy and the framework determined by ARPA-H. This work builds on Palantir's experience providing data infrastructure and AI tools to support public health initiatives including creating the secure collaborative research platform for N3C; ongoing tooling for disease surveillance at HHS and CDC; and increasing speed of drug review at the FDA.